<DOC>
	<DOCNO>NCT02795429</DOCNO>
	<brief_summary>The purpose study INC280 PDR001 characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) antitumor activity PDR001 administer i.v . single agent combination INC280 administer orally adult patient advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Phase Ib/II Study INC280 + PDR001 PDR001 Single Agent Advanced HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Histologically cytologically document locally advanced recurrent metastatic HCC patient cirrhosis accord American Association Study Liver Diseases ( AASLD ) criterion . Current cirrhotic status Child Pugh Class A ( 56 point ) , encephalopathy and/or ascites . 2 . Patients must receive prior systemic sorafenib treatment HCC document progression discontinuation sorafenib treatment ( France : patient must receive least 8 week prior sorafenib treatment ) , intolerant sorafenib ( define document Grade 3 4 adverse event lead sorafenib discontinuation ) . 3 . ECOG Performance Status ≤ 1 . 4 . Willing able swallow retain oral medication . Other protocol define Inclusion criterion may apply . 1 . Use vaccine ( except inactivate seasonal influenza vaccine ) within 4 week initiation study treatment . 2 . History severe hypersensitivity reaction monoclonal antibody ( mAbs ) . 3 . Clinically significant pleural effusion either required pleurocentesis associate shortness breath . 4 . Active autoimmune disease document history autoimmune disease . 5 . Clinically significant , uncontrolled heart disease . 6 . Patient range laboratory value define : Total bilirubin &gt; 2 mg/dL , except patient Gilbert 's syndrome exclude total bilirubin &gt; 3.0 x ULN direct bilirubin &gt; 1.5 x ULN Alanine aminotransferase ( ALT ) &gt; 5 x ULN Aspartate aminotransferase ( AST ) &gt; 5 x ULN Coagulation : Prothrombin Time ( PT ) ≥ 4 second International Normalized Ratio ( INR ) ≥ 1.7 Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L Platelet count &lt; 75 x 109/L Hemoglobin &lt; 9 g/dL Creatinine clearance ( calculate use CockcroftGault formula , measure ) &lt; 45 mL/min Asymptomatic serum amylase grade &gt; 2 ( 1.52.0 x ULN ) . Patients grade 1 grade 2 serum amylase begin study must confirm sign symptom suggest pancreatitis pancreatic injury ( e.g. , elevated Pamylase , abnormal imaging finding pancreas , etc . ) Serum lipase &gt; ULN Potassium , Magnesium , Phosphorus , total Calcium ( correct serum albumin ) outside normal limit ( patient may enrol correct within normal limit supplement screen ) Other protocoldefined Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase Ib/II</keyword>
	<keyword>INC280</keyword>
	<keyword>PDR001</keyword>
	<keyword>checkpoint inhibitor</keyword>
	<keyword>PD-1</keyword>
</DOC>